Vogenx Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | VOGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVOGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −288.4x | −3.7x | −0.4x | |
PEG Ratio | - | −0.26 | 0.00 | |
Price/Book | −322.3x | −7.6x | 2.6x | |
Price / LTM Sales | - | 2.5x | 3.0x | |
Upside (Analyst Target) | 69.6% | 89.2% | 54.5% | |
Fair Value Upside | Unlock | 14.1% | 7.8% | Unlock |
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.